{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"KPS Score = 70"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"KPS Score = 80"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"KPS Score = 90"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"KPS Score = 100"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.","groups":[{"description":"Participants received 1.3 mg per m\\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.","id":"OG000","title":"Bortezomib"}],"paramType":"NUMBER","populationDescription":"The FAS population included all the participants who received 1 dose of study medication and had post-dose efficacy data.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1","title":"Number of Participants With KPS Score at Day 1 of Cycle 1","type":"PRIMARY","unitOfMeasure":"Participants"}